Prescrire, along with around 20 civil society organisations, has signed a joint declaration drawing attention to potential problems posed by the provision of confidential scientific advice by the European Medicines Agency to pharmaceutical companies, in particular a lowering of the regulatory bar, a risk of regulatory capture, and a total lack of transparency surrounding the activity of European regulatory authorities. Read on...